Epidermal growth factor (EGF) is a 53 amino acid peptide, mol. wt 6045, initially isolated from the submaxillary glands of adult male mice (Cohen, 1962;  Cohen & Taylor, 1974; Carpenter & Cohen, 1979) . Mouse EGF (mEGF) stimulated precocious eyelid opening and incisor eruption in newborn mice due to promotion of epidermal growth and increased keratinization (Cohen, 1962; Cohen & Elliott, 1963; Carpenter & Cohen, 1979) . A polypeptide from human urine, urogastrone, which inhibits gastric acid secretion and promotes gastric mucosal healing, is probably the human equivalent (hEGF) of mouse EGF (Gregory, 1975) . The two polypeptides are highly homologous, have identical biological effects and cross-react in many antibody systems (Cohen & Carpenter, 1975; Gregory, 1975; Carpenter & Cohen, 1979) . Epidermal growth factor stimulates growth of a wide variety of epidermal cells in vivo and in vitro, including transformed lines, and of many mesodermal cells including mouse and human fibroblasts and vascular endothelial cells (Gospodarowicz et al., 1978; Cohen & Taylor, 1974; Carpenter & Cohen, 1979) .
In man, hEGF occurs in submandibular glands and Brunners glands (Elder et al., 1978) and in much lower concentrations in the thyroid gland, jejunum and kidney (Hirata & Orth, 1979) . Epidermal growth factor inhibits gastric acid secretion in man, dogs and rats (Gregory, 1975; Bower et al., 1975; Koffman et al., 1982) , while non-anti-secretory doses protect the gastric mucosa of cats and rats from aspirin-induced ulceration, by increasing DNA synthesis (Konturek et al., 1981 (Forgue-Lafitte et al., 1980) , and mEGF stimulates DNA synthesis and cell proliferation in adult murine intestine (Scheving et al., 1979 (Scheving et al., , 1980 AlNafussi & Wright, 1982a; Chabot et al., 1983) , and the development of gastrointestinal enzyme activities in suckling mice (Malo & Menard, 1982) .
Treatment with melphalan in mouse and man is limited by bone marrow depression, which may be circumvented by autologous marrow transplantation, and by gastrointestinal mucosal toxicity (Millar et al., 1978; McElwain et al., 1979 ).
Because EGF is trophic for the mouse gastrointestinal tract and protects the gastric mucosa from ulceration, EGF might protect the gastrointestinal tract from melphalan damage or enhance its recovery. We have explored this possibility in mice and present herewith our preliminary results.
Materials and methods
Adult male and female CBA/ca mice, at least 12 weeks old weighing 20-30gm, were maintained at 22°C with food and water ad libitum. Melphalan and hEGF administration and assays were all performed at the same times throughout this study to eliminate effects from circadian variation in mouse gastrointestinal tract proliferation (Scheving et al., 1979 (Scheving et al., , 1980 Al-Nafussi &Wright, 1982b following Cohen (1962) and Moore et al. (1981 On days 4, 7 or 8, and 13 after melphalan treatment groups of mice were killed, the intestine excised and surviving cryptogenic cells assessed using a modification of the method of Withers & Elkind (1970) , described by Millar et al. (1978) . Two or three segments of jejunum and one each of ileum and colon were taken from each mouse. The number of regenerating crypts per circumference of transverse 4-5 pm formalin-fixed sections stained with haematoxylin and eosin, were expressed as a percentage of the number of crypts per circumference in normal mice.
Results are presented as the mean (±s.e.) for 3-6 mice, or of the ratio for percentages, and compared using the t-test for small samples.
Results
Melphalan, hEGf and gut damage at 4 and 7 days Groups of 3 mice were treated with melphalan, 15 or 20 mg kg-1, or saline, i.p. Two hours before melphalan or saline treatment hEGF (100 pg kg -1) or water was administered i.p. and continued 8 hourly for 4 days (total 12 doses). Jejunum microcolonies and ['4C]-xylose uptake were determined on days 4 and 7 (Figure 1) .
The melphalan-treated mice all lost weight, and the loss tended to be greater with hEGF. Uptake of
[14C]-xylose showed no significant differences from controls, nor any effect of hEGF treatment. Treatment with hEGF further reduced jejunal crypt survival after melphalan 15mgkg-1 i.p. from 97% to 71% (P<0.02) on day 4, and from 90% to 73% (P<0.05) on day 7. Treatment with hEGF alone had no effect in either assay. This suggested that commencing hEGF 2h before melphalan might be detrimental and other regimens were therefore explored.
Six different regimens of hEGF administration
Groups of 3 mice received melphalan (17.5mgkg 1; i.p.) on day 0, with hEGF i.p. in one of 6 regimens shown on Table I . When hEGF was given on day 0, it preceded melphalan by 2 h, except in group 6 where hEGF was commenced 6h after melphalan. On day 4, [14C]-xylose uptake and gut microcolonies were assessed ( (Figure 2 ).
Human EGF begun 6 h after melphalan treatment had no effect on survival of jejunal crypts or ileum crypts at 8 or 13 days. However, ileum crypt survival was not reduced by melphalan (15mgkg-1, i.p.) (Figure 2a ). Colon crypt survival was not affected by melphalan 15mgkg-t i.p. or by hEGF (data not shown). The low value of [14C]-xylose uptake in control mice on day 8 is unexplained, but none of the treated groups differed significantly from the day 4 control value or from each other. Delaying hEGF treatment until 4 days after melphalan had no significant effect on gastrointestinal recovery (Figure 2b ). All the treated mice lost weight, with a nadir at 4-5 days, recovery by day 8, with no detectable effect of hEGF. Oral hEGF and melphalan gut damage Melphalan (20mg kg -1, i.p.) was given to 2 groups of 5 mice on day 0. One group received hEGF (100 pg kg-1) by oropharyngeal tube under light ether anaesthesia twice daily (9 doses), and the other group anaesthesia only, beginning immediately before melphalan administration. On day 4, there was no difference in gastrointestinal toxicity between the group treated with topical hEGF and controls treated only with melphalan (20mgkg-1, i.p.) (Figure 3) . (Millar et al., 1978) . However, the jejunum may be the segment least affected by exogenous EGF. Synthesis of DNA and cell proliferation in mouse intestine follows a circadian rhythm (Scheving et al., 1979 (Scheving et al., , 1980 Al-Naffusi & Wright, 1982b) , which may be related to the circadian periodicity of EGF in the male mouse submaxillary gland controlled by the sympathetic nervous system in response to the dark-light cycle or to feeding (Krieger et al., 1976) . The extent of stimulation of gastrointestinal proliferation by EGF depends on the part of the intestine, its phase in the cycle (Scheving et al., 1979 (Scheving et al., , 1980 and on feeding (Chabot et al., 1983) .
In fasted mice, mEGF (25 pg per mouse) increased DNA synthesis in the jejunum, ileum and colon (Chabot et al., 1983) , but not in the jejunum of fed mice (Scheving et al., 1979; Chabot et al., 1983) . Cell production, by vincristine metaphase arrest, was also not increased in the jejunum of fed mice after mEGF, 10 pg kg -1, 8 hourly for 6 doses (Al-Nafussi & Wright, 1982a) . Melphalan-treated mice tend not to eat and might resemble fasted mice, who have lower serum levels of endogenous EGF (Chabot et al., 1983) . However, melphalan damage might promote endogenous EGF release and stimulation so that exogenous EGF is ineffective.
The dosage, mode of administration and timing of hEGF should have been adequate to detect an effect if hEGF has the same biological effects as mEGF in mie.= Thus to 0pgkg-1, up to 8 hourly for up to 10"days, and 10Opgkg-1 (25 pg per 25g mouse) i.p., span the doses and times of administration of mEGF which affect DNA synthesis and cell proliferation in murine intestine (Scheving et al., 1979 (Scheving et al., , 1980 Al-Naffusi & Wright, 1982a, b; Chabot' et al., 1983) . Precocious eyelid opening in newborn mice requires daily doses of 1-4mgkg-1 mEGF, although 0.3mgkg-1 has a detectable effect (Cohen, 1962; Moore et al., 1981) ; hEGF has a similar potency (Gregory, 1975) . The close homology between mEGF and hEGF makes it unlikely that failure.to show a protective effect in murine intestine is due to the use of hEGF. Indeed, mEGF, 100pgkg-1 i.p. twice daily for 4 days failed to protect murine jejunum from melphalan (unpublished observations).
The conclusion from this study is that hEGF, in the doses and regimens employed, did not protect the mouse gastrointestinal tract and particularly the jejunum, from melphalan damage, nor did it enhance epithelial recovery. No optimal timing of hEGF administration with respect to melphalan emerged. However, different scheduling of hEGF with respect to melphalan and different frequency and mode of administration of hEGF might be successful. It remains an attractive possibility to protect normal tissue with a growth factor to enable administration of melphalan with less toxicity or in higher doses. There must be caution, however, in view of the stimulatory effects of EGF on transformed as well as normal cells.
